Prognosis of pulmonary arterial hypertension - ACCP evidence-based clinical practice guidelines
Prognosis of pulmonary arterial hypertension - ACCP evidence-based clinical practice guidelines
复制标题
DOI：
10.1378/chest.126.1_suppl.78s
复制
发表时间：
2004-07-01
期刊：
影响因子：
9.6
通讯作者：
Ahearn, G
中科院分区：
文献类型：
--
作者：
McLaughlin, VV;Presberg, KW;Ahearn, G
虽然特发性肺动脉高压被认为是一种进展性疾病，结局一致较差，但疾病的自然史是异质性的，一些患者在诊断后几个月内死亡，另一些患者存活数十年。医学疗法的进步也改变了疾病的进程。其他类型肺动脉高压（PAH）患者的结局特征不太清楚。评估此类患者的预后是重要的，因为它影响药物治疗和移植转诊。本章将提供评估PAH患者预后的循证建议。
Although idiopathic pulmonary arterial hypertension is perceived as a progressive disease with a uniformly poor outcome, the natural history of disease is heterogeneous, with some patients dying within months of diagnosis and others living for decades. The course of the disease has also been altered by advances in medical therapies. The outcome of patients with other types of pulmonary arterial hypertension (PAH) has been less well characterized. Assessment of prognosis of such patients is important, as it influences both medical therapy and referral for transplantation. This chapter will provide evidence based recommendations to assess the prognosis of patients with PAH.